LT3209302T - Provaistai karbidopa ir l-dopa ir jų panaudojimas parkinsono ligai gydyti - Google Patents

Provaistai karbidopa ir l-dopa ir jų panaudojimas parkinsono ligai gydyti

Info

Publication number
LT3209302T
LT3209302T LTEP15791424.3T LT15791424T LT3209302T LT 3209302 T LT3209302 T LT 3209302T LT 15791424 T LT15791424 T LT 15791424T LT 3209302 T LT3209302 T LT 3209302T
Authority
LT
Lithuania
Prior art keywords
carbidopa
disease
treat parkinson
dopa prodrugs
dopa
Prior art date
Application number
LTEP15791424.3T
Other languages
English (en)
Lithuanian (lt)
Inventor
Benoit Cardinal-David
Vincent S. Chan
Kassibla E. Dempah
Brian P. Enright
Rodger F. Henry
Raimundo Ho
Ye Huang
Alexander D. Huters
Russell C. Klix
Scott W. Krabbe
Philip R. Kym
Yanbin Lao
Xiaochun Lou
Sean E. MACKEY
Mark A. Matulenko
Peter T. Mayer
Christopher P. Miller
James Stambuli
Eric A. Voight
Zhi Wang
Geoff G. Zhang
Valentino J. Stella
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3209302(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of LT3209302T publication Critical patent/LT3209302T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP15791424.3T 2014-10-21 2015-10-21 Provaistai karbidopa ir l-dopa ir jų panaudojimas parkinsono ligai gydyti LT3209302T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
PCT/US2015/056686 WO2016065019A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Publications (1)

Publication Number Publication Date
LT3209302T true LT3209302T (lt) 2019-06-10

Family

ID=54478240

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP15791424.3T LT3209302T (lt) 2014-10-21 2015-10-21 Provaistai karbidopa ir l-dopa ir jų panaudojimas parkinsono ligai gydyti
LTPA2023519C LTC3209302I2 (index.php) 2014-10-21 2023-06-08

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2023519C LTC3209302I2 (index.php) 2014-10-21 2023-06-08

Country Status (37)

Country Link
US (7) US9446059B2 (index.php)
EP (3) EP3569587A1 (index.php)
JP (6) JP6567049B2 (index.php)
KR (3) KR20230066484A (index.php)
CN (4) CN111454290B (index.php)
AR (1) AR102389A1 (index.php)
AU (4) AU2015335941B2 (index.php)
BR (1) BR112017008198B1 (index.php)
CA (1) CA2965379A1 (index.php)
CY (2) CY1121826T1 (index.php)
DK (1) DK3209302T3 (index.php)
ES (1) ES2739536T3 (index.php)
FI (1) FIC20230014I1 (index.php)
FR (1) FR23C1035I2 (index.php)
HR (1) HRP20191285T1 (index.php)
HU (2) HUE044115T2 (index.php)
IL (3) IL251829B (index.php)
LT (2) LT3209302T (index.php)
LU (1) LUC00304I2 (index.php)
MX (2) MX393568B (index.php)
MY (1) MY189519A (index.php)
NL (1) NL301224I2 (index.php)
NO (1) NO2023013I1 (index.php)
PH (1) PH12017500746B1 (index.php)
PL (1) PL3209302T3 (index.php)
PT (1) PT3209302T (index.php)
RS (1) RS58972B1 (index.php)
RU (2) RU2021103000A (index.php)
SA (1) SA521421115B1 (index.php)
SG (1) SG11201703170RA (index.php)
SI (1) SI3209302T1 (index.php)
SM (1) SMT201900376T1 (index.php)
TR (1) TR201908296T4 (index.php)
TW (2) TWI755257B (index.php)
UA (1) UA120437C2 (index.php)
WO (1) WO2016065019A1 (index.php)
ZA (1) ZA201702760B (index.php)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022320B2 (en) 2014-03-13 2018-07-17 Neuroderm, Ltd. Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CN111454290B (zh) 2014-10-21 2022-12-23 艾伯维公司 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
JP2019515908A (ja) * 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
WO2017223182A1 (en) * 2016-06-22 2017-12-28 Medchem Partners, Llc. Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
AR113908A1 (es) 2017-11-24 2020-06-24 H Lundbeck As Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
CN112770734B (zh) 2018-09-13 2024-08-20 堪培拉大学 抑制方法
TW202031265A (zh) * 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
JP7514859B2 (ja) 2019-05-21 2024-07-11 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US12391650B2 (en) 2019-05-21 2025-08-19 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
CN113727979B (zh) 2019-05-21 2024-09-20 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
WO2020234277A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
ATE118216T1 (de) * 1989-04-20 1995-02-15 Zambon Spa Dopamin-medikament-vorstufe.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6576766B1 (en) * 1997-11-12 2003-06-10 Ariad Pharmaceuticals, Inc. Signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
EP1541579A1 (en) 2002-06-20 2005-06-15 Nippon Suisan Kaisha, Ltd. Produrg, medicinal utilization thereof and process for producing the same
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
EP1596808A4 (en) 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
DE602004031134D1 (de) 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
US20060094782A9 (en) 2003-10-31 2006-05-04 Wong Patrick S Compositions and dosage forms for enhanced absorption
DK1751087T3 (da) 2004-06-04 2012-07-16 Xenoport Inc Levodopa-derivater og sammensætninger og anvendelser deraf
WO2006014282A2 (en) 2004-07-06 2006-02-09 Abbott Laboratories Prodrugs of hiv protease inhibitors
DK1959948T3 (da) * 2005-12-05 2012-08-20 Xenoport Inc Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf
KR20090057349A (ko) * 2006-05-31 2009-06-05 솔베이 파머슈티컬스 게엠베하 레보도파／칼비도파의 ２４시간의 장기간 장내투여
JP2009539942A (ja) * 2006-06-16 2009-11-19 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ビフェプルノックス及びｌ−ｄｏｐａを含む組み合わせ製剤
EP2125702A1 (en) 2006-12-21 2009-12-02 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
ATE510537T1 (de) * 2008-02-06 2011-06-15 Wockhardt Research Center Pharmazeutische zusammensetzungen von entacapon, levodopa und carbidopa mit verbesserter bioverfügbarkeit
EP2291348A4 (en) 2008-05-20 2013-05-15 Neurogesx Inc WATER-SOLUBLE ACETAMINOPHENANALOGA
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
MX2011012315A (es) 2009-05-19 2011-12-16 Neuroderm Ltd Composiciones para la administracion continua de inhibidores de dopa descarboxilasa.
US8435562B2 (en) 2009-11-09 2013-05-07 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
WO2011109767A2 (en) 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
EP3326615B1 (en) 2010-11-15 2020-01-08 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
JP5423905B2 (ja) 2010-12-02 2014-02-19 小野薬品工業株式会社 新規化合物及びその医薬用途
CA2823642A1 (en) 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US8765189B2 (en) * 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
PT2968218T (pt) 2013-03-13 2021-09-24 Neuroderm Ltd Combinação para tratamento da doença de parkinson
WO2014139161A1 (en) 2013-03-15 2014-09-18 Techfields Pharma Co., Ltd. Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
CN111454290B (zh) * 2014-10-21 2022-12-23 艾伯维公司 卡比多巴和左旋多巴前药及它们治疗帕金森病的用途
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
JP2019515908A (ja) 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
WO2018059739A1 (en) 2016-09-29 2018-04-05 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
FIC20230014I1 (fi) 2023-03-31
TW202131931A (zh) 2021-09-01
US20180079762A1 (en) 2018-03-22
SMT201900376T1 (it) 2019-09-09
JP2025118978A (ja) 2025-08-13
CN111362980A (zh) 2020-07-03
AU2025238004A1 (en) 2025-10-16
KR20170071599A (ko) 2017-06-23
RU2021103000A (ru) 2021-03-01
JP7688087B2 (ja) 2025-06-03
US9446059B2 (en) 2016-09-20
KR20230066484A (ko) 2023-05-15
IL268885B (en) 2020-08-31
EP4186510A1 (en) 2023-05-31
TWI718999B (zh) 2021-02-21
MX2021003840A (es) 2022-06-30
US10730895B2 (en) 2020-08-04
AU2021201414A1 (en) 2021-03-25
HUE044115T2 (hu) 2019-10-28
CY2023010I2 (el) 2023-06-09
DK3209302T3 (da) 2019-05-13
JP2017537066A (ja) 2017-12-14
JP2020189864A (ja) 2020-11-26
HUS2300009I1 (hu) 2023-03-28
UA120437C2 (uk) 2019-12-10
RU2017117413A3 (index.php) 2019-05-30
PT3209302T (pt) 2019-07-19
LTC3209302I2 (index.php) 2025-10-10
IL276493A (en) 2020-09-30
NL301224I1 (index.php) 2023-03-29
WO2016065019A1 (en) 2016-04-28
LUC00304I2 (index.php) 2025-09-22
BR112017008198A2 (pt) 2017-12-26
PH12017500746B1 (en) 2021-12-15
US20220153765A1 (en) 2022-05-19
AU2015335941A1 (en) 2017-05-04
JP6567049B2 (ja) 2019-08-28
RS58972B1 (sr) 2019-08-30
US11091507B2 (en) 2021-08-17
MY189519A (en) 2022-02-16
RU2017117413A (ru) 2018-11-26
EP3209302B1 (en) 2019-04-24
SI3209302T1 (sl) 2019-06-28
CY1121826T1 (el) 2020-07-31
NZ730996A (en) 2024-04-26
BR112017008198B1 (pt) 2021-02-09
KR20240113982A (ko) 2024-07-23
US20230106081A1 (en) 2023-04-06
FR23C1035I1 (fr) 2023-12-08
CA2965379A1 (en) 2016-04-28
EP3209302A1 (en) 2017-08-30
AU2023210650A1 (en) 2023-08-24
CN111494395B (zh) 2024-06-21
RU2743347C2 (ru) 2021-02-17
TWI755257B (zh) 2022-02-11
NL301224I2 (nl) 2023-08-16
IL268885A (en) 2019-10-31
CN111454290A (zh) 2020-07-28
CN111362980B (zh) 2022-10-18
FR23C1035I2 (fr) 2025-04-18
CN107206013A (zh) 2017-09-26
ZA201702760B (en) 2022-05-25
US20190375770A1 (en) 2019-12-12
CN111454290B (zh) 2022-12-23
LTPA2023519I1 (index.php) 2023-06-26
JP2019218356A (ja) 2019-12-26
PL3209302T3 (pl) 2019-10-31
AR102389A1 (es) 2017-02-22
MX393568B (es) 2025-03-24
CN111494395A (zh) 2020-08-07
US20200262852A1 (en) 2020-08-20
US10174061B2 (en) 2019-01-08
SG11201703170RA (en) 2017-05-30
TW201630924A (zh) 2016-09-01
EP3569587A1 (en) 2019-11-20
IL251829A0 (en) 2017-06-29
NZ769153A (en) 2024-04-26
IL251829B (en) 2019-09-26
HRP20191285T1 (hr) 2019-10-18
JP2023174770A (ja) 2023-12-08
JP6750076B2 (ja) 2020-09-02
TR201908296T4 (tr) 2019-06-21
PH12017500746A1 (en) 2017-10-30
MX2017005236A (es) 2017-07-26
MX381069B (es) 2025-03-12
US20160362431A1 (en) 2016-12-15
KR102537018B1 (ko) 2023-05-30
ES2739536T3 (es) 2020-01-31
AU2015335941B2 (en) 2021-04-01
AU2021201414B2 (en) 2023-05-11
NO2023013I1 (no) 2023-03-20
JP6932227B2 (ja) 2021-09-08
SA521421115B1 (ar) 2022-03-01
CY2023010I1 (el) 2023-06-09
JP2021183628A (ja) 2021-12-02
US20160106765A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
IL276493A (en) Carbidopa and L-dopa prodrugs and methods for use in the treatment of Parkinson's disease
ZA201606158B (en) Treatment of metabolic disorders in equine animals
IL248469A0 (en) Preparations and methods for the treatment of hemoglobin diseases
IL251530A0 (en) Use of cannabinoids in the treatment of skeletal muscle atrophy
PL3096765T3 (pl) Leczenie zaburzeń metabolicznych u zwierząt psowatych
ZA201703507B (en) Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
IL265719B1 (en) Fabp4 as a therapeutic target in skin diseases
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
PT3180434T (pt) Chamarizes oligonucleotídicos para o tratamento da dor
GB201417215D0 (en) Improvements in or relating to wearable monitors
EP3126500A4 (en) Dna aptamers specific to cd200r1 and their therapeutic uses
GB201601456D0 (en) Improvements relating to retinal treatment
PL3099500T3 (pl) Zasobniki atramentu i sposoby przygotowywania zasobników atramentu
EP3110793A4 (en) Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
GB201421889D0 (en) Improvements in or relating to effluent treatment
PT3200785T (pt) Tratamento da perturbação de dor extrema paroxística
PT3721882T (pt) Tratamento de disfunção da pars intermédia da pituitária em animais equinos
PT3485890T (pt) Inibidores de sglt2 para o tratamento de distúrbios metabólicos em animais caninos
GB201415915D0 (en) Improvements in and Relating to ophthalmoscopes
AU358216S (en) A flexible gemstone setting
GB201410990D0 (en) General cure to diseases
TWM489640U (en) Scalp massager